Important Notice and Disclaimers This presentation contains forward-looking statements and information relating to Nurix Therapeutics, Inc. (the "Company," "we," "us" or "our"). Forward-looking statements are neither his

Nurix Therapeutics Blazing a New Path

in Medicine Targeted Protein Modulation: Harnessing or Inhibiting E3 Ligases to Decrease or Increase Protein Levels TPD Conference 2020 Exhibit 99.1

Important Notice and Disclaimers This

presentation contains forward-looking statements and information relating to Nurix Therapeutics, Inc. (the "Company," "we," "us" or "our"). Forward-looking statements are neither historical facts nor assurances of future

performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical results and other future conditions. All statements,

other than statements of historical facts, contained in this presentation are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our future financial or business

performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective product candidates; the timing of our planned IND submissions for our product candidates; the potential advantages

of our DELigase platform and product candidates, including NX-1607 and NX-0255; the extent animal model data predicts human efficacy; and the success and timing of our development and commercialization of our product candidates, including our

DeTIL and DeCART opportunities. In addition, when or if used in this presentation, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect,"

"intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Although we believe the expectations reflected in such

forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, performance or events and circumstances could differ materially from

those expressed or implied in our forward-looking statements due to a variety of factors, including risks and uncertainties related to our ability to advance our product candidates; obtain regulatory approval of and ultimately commercialize our

product candidates; the timing and results of preclinical and clinical trials; our ability to fund development activities and achieve development goals; the impact of the COVID-19 pandemic on our business; our ability to protect intellectual

property; and other risks and uncertainties described under the heading "Risk Factors" in our final prospectus pursuant to Rule 424(b)(4) filed with the Securities and Exchange Commission (the "SEC") on July 24, 2020 and in

our Quarterly Report on Form 10-Q for the quarter ended August 31, 2020, as well as other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do

not plan to publicly update or revise any forward-looking statements contained herein. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and

the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy,

fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the

Nurix Therapeutics. All rights

reserved. Targeting E3 ligases to develop small molecule targeted protein modulation drug candidates that can increase or decrease protein levels Four wholly-owned oncology and immunology drug candidates with first clinical trial expected to

commence in H1 2021 Applying targeted protein modulation to create new adoptive cell therapies for cancer and to discover anti viral drugs DELigaseTM: a versatile drug discovery platform comprised of massive DNA-encoded libraries to screen an

expanded universe of E3 ligases Revenue generating drug discovery partnerships with Sanofi and Gilead BB2 BB3 BB1 Pipeline Partners: Gilead Sanofi Technology E3 Ligase Nurix: A Targeted Protein Modulation Company *Expected IND submission timing

based on calendar year quarters

DELigaseTM: Platform Enables Two

ligases, >30 ligases currently in discovery Ability to push protein levels in either direction 1 2 3 Inhibitors of E3 Ligases Chimeric Targeting Molecules (CTMs) Decrease specific protein levels Ligase Inhibitors Increase specific protein levels

Harnesses of E3 Ligases

DELigaseTM Identifies a Spectrum of

Ligase Inhibitors Can Increase Levels

Protein Proteasomal Degradation Catalytic ubiquitination Nurix Ligase Inhibitor Substrate protein levels increase E3 Ligase-mediated proteasomal degradation can be highly specific to decrease substrate proteins Substrate Proteins Substrate Proteins

E3 Ligase Ubiquitin E3 Ligase

Drug Candidate Target / Delivery

Therapeutic Area Lead Optimization Preclinical Phase 1 Phase 2 Phase 3 Protein Degradation Chimeric Targeting Molecule (CTM) Portfolio NX-2127 BTK + IMiD activity Oral B-cell Malignancies NX-5948 BTK Oral B-cell Malignancies And GVHD Ligase

Nurix's Wholly-Owned Targeted Protein Modulation Drug Pipeline: Multiple Clinical Programs Expected Next Year *Expected IND submission timing based on calendar year quarters

CBL-B: A Modulator of T Cell Activation

for Tumor Immunotherapy CBL-B is an E3 ligase that regulates the immune system by specifically degrading proteins involved in shutting off T-cell signaling Blocking CBL-B removes a brake on the immune system CBL-B function is supported by mouse and

human genetics CBL-B inhibitors have remarkable effects on T cells CBL-B inhibitors induce immune cells to secrete IL-2 Skewing T cells to a central memory phenotype Ex vivo and in vivo administration of CBL-B inhibitors demonstrate anti-tumor

CBL-B Knockout Validation: Enhanced

Nurix CBL-B Inhibitors Elevate IL-2

in the absence of co-stimulation with CD3 and CD28, a potential advantage in a suppressive tumor microenvironment

Once Daily Oral Dosing of NX-1607

Average tumor volumes from both flanks are depicted Tumor growth inhibition (TGI) with NX-1607 treatment; tumors implanted at Day 0; once daily oral dosing of NX-1607 was given from Day 9 to Day 28 Anti-tumor effects in ligase-inactive, knock-in

NX-1607 and Anti-PD-1 Synergize to

anti-tumor response and survival in mice bearing two tumors relative to vehicle or anti-PD-1 alone Tumors from both flanks plotted Two-way ANOVA of treatment group vs vehicle control ** **** Treatment Period Anti-PD-1 antibody, Oral NX-1607 CBL-B

inhibitor, and Combined Treatment

NX-1607 Induces Long Term Survival

Surgical removal of primary Log-rank (Mantel-Cox) test of treatment vs Vehicle Dosing period Once daily oral dosing of NX-1607 Tumors implanted at Day 0 Surgical removal of primary tumor at Day 15 NX-1607 was given before the surgery from day 7 to

day 15 (neo-adjuvant phase) and continued after surgery until day 46.

Introducing Pharmacologic Control of

Antigen Receptor T Cell Therapy Small molecule targeted protein modulation: CBL-B Inhibitors Convergence

NX-0255 ex vivo Treatment Provides

resulted in superior conditional survival compared to using IL-2 alone CD8+ cells exposed to NX-0255 and IL-2 combined ex vivo exert a deeper anti-tumor response NX-0255 ex vivo exposure period is only three days, anti-tumor effects persist for over

a month after engraftment Animals that rejected tumor were rechallenged 80 days post ACT. All animals rejected tumor, demonstrating immunological memory

Oral NX-1607 Augments Anti-Tumor

treatment once daily further enhances conditional survival and anti-tumor activity of T cells expanded for three days with recombinant IL-2 plus NX-0255 ex vivo in adoptive cell therapy mouse model

CBL-B Inhibitors to Enhance Adoptive

of T cells for TIL or CAR-T therapy Ex-vivo CBL-B inhibition For ACT expansion phase to enhance cellular phenotype General schema for growing patient T cells ex vivo for adoptive cell therapy (ACT ) Oral NX-1607 Ex vivo NX-0255 DeTIL and DeCART

created by ex vivo CBL inhibition with small molecule NX-0255 producing a TIL and CAR-T cell therapy products with enhanced characteristics An oral small molecule immunotherapy drug candidate in development as a single agent or in combination with

other oncology therapies including adoptive cell therapy

Matching the Right Business Strategy

Philadelphia by industry leading cell therapy experts Key recruits bring significant cell therapy experience Michael T. Lotze, M.D. Chief Cellular Therapy Officer Formerly CSO at Iovance Robert J. Brown, M.D. Vice President of Clinical Development

Formerly Allogene and Iovance Wholly owned subsidiary seeded with $3M and a license to three Nurix compounds for combination use with CAR-T to enable independent investment Industry leader and DeCART founder Dr. Carl June to lead Scientific Advisory

Board Chief Operating Officer, Dana Hammill, former director of strategy and business development at the Center for Cellular Immunotherapies University of Pennsylvania where she co-managed Penn-Novartis alliance for commercialization of CART19

Summary DELigase has produced highly

potent hits to ligases Specific ligase inhibitors can result in pathway-specific changes in ubiquitination status associated with potent biologic effects CBL-B inhibitors activate T cells and demonstrate single agent and combination anti-tumor

submission timing based on calendar year quarters